A small study found a significant effectivenes of pioglitazone (an approved diabetes typ-II drug) in protecting grey matter and a positive trend towards lower lesion load:
PubMed
--Frank
Pilot-trial results of INF+pioglitazone
Pilot-trial results of INF+pioglitazone
Treatment: Gilenya since 01/2011, CCSVI both IJV ballooned 09/2010, Tysabri stopped after 24 Infusions and positive JCV antibody test, after LDN, ABX Wheldon Regime for 1 year.